A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichiacoli-Reference-Cited by-同舟云学术

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichiacoli

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Zhou Junxin¹²³,Wang Weiping⁴,Liang Min¹²³,Yu Qian¹²³,Cai Shiqi¹²³,Lei Tailong¹²³^ORCID,Jiang Yan¹²³,Du Xiaoxing¹²³,Zhou Zhihui¹²³,Yu Yunsong¹²³^ORCID

Affiliation:

1. Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

2. Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Hangzhou, China

3. Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

4. Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China

Abstract

Ceftazidime-avibactam is a novel β-lactam–β-lactamase inhibitor (BLBLI) combination with powerful activity against Enterobacterales isolates producing AmpC, such as CMY-like cephalosporinase. However, in recent years, CMY variants have been reported to confer ceftazidime-avibactam resistance.

Funder

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

NSFC | NSFC-Zhejiang Joint Fund | 浙江省科学技术厅 | Natural Science Foundation of Zhejiang Province

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.03349-22

Reference45 articles.

1. Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections

2. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014

3. Resistance to ceftazidime–avibactam and underlying mechanisms

4. Multidrug resistance IncC plasmid carrying blaCMY-97 in Shiga toxin-producing Escherichia coli ST215-H54 of ovine origin

5. Contemporary IncI1 plasmids involved in the transmission and spread of antimicrobial resistance in Enterobacteriaceae

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance;International Journal of Antimicrobial Agents;2024-09

2. Mecanismos moleculares y epidemiología de la resistencia a ceftazidima-avibactam: un análisis integral;Acta Pediátrica de México;2024-07-25

3. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli;Frontiers in Cellular and Infection Microbiology;2024-04-04

4. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185;mBio;2024-02-14

5. Drug Discovery in the Field of β-Lactams: An Academic Perspective;Antibiotics;2024-01-08